Amgen executives detailed their alleged Aranesp "overfill" kickback scheme in a set of PowerPoint slides and Excel spreadsheets, according to a lawsuit filed by the New York State Attorney General.

DUBLIN--(BUSINESS WIRE)--The "Darbepoetin Alfa (Aranesp) Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The global darbepoetin alfa (Aranesp) market is expected ...

Amgen’s anaemia drug Aranesp has been dealt a further blow after it was confirmed that full results from a Phase III clinical study showed a higher rate of death in cancer patients receiving the drug.

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio Aranesp use has increased from 2.5% in ...

The study showed patients treated with Aranesp had a reduction in the number of red blood cell transfusions Amgen announced positive results from the Phase 3 ARCADE study evaluating Aranesp ...

ORLANDO, Fla., (May 15, 2005) – Amgen Inc., (NASDAQ: AMGN) the world's largest biotechnology company, today announced that new interim data from a single-arm, open label study of 1,225 cancer patients ...

NEW YORK, Feb 16 (Reuters) - Amgen Inc.'s multibillion-dollar anemia drug Aranesp is facing further safety concerns after a medical newsletter reported on Friday that a Danish study of the drug in ...

ORLANDO, Fla., (May 15, 2005) – Amgen Inc., (NASDAQ: AMGN) the world's largest biotechnology company, today announced that final results of a Phase 3 randomized, head-to-head study demonstrated that ...

LOS ANGELES (Reuters) - Amgen Inc. said on Monday that 48.5 percent of cancer patients not undergoing chemotherapy or radiation who received its anemia drug Aranesp in a clinical trial died compared ...

Biotechnology giant Amgen today pleaded guilty in federal court to a misdemeanor charge of misbranding Aranesp (darbepoetin alfa), its highly successful anemia drug. The government accused Amgen of ...

Once again a trial testing the erythropoiesis-stimulating agent darbepoetin alfa (Aranesp, Amgen) has produced a negative result. Results of the RED-HF (Reduction of Events by Darbepoetin Alfa in ...